News

Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced a scientific consulting program aimed at optimizing imaging processes and outcomes to accelerate the clinical development of...

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing...

Merck, a leading science and technology company, announced an agreement with Alteogen, Inc., of South Korea, providing late-stage CDMO services through Merck’s BioReliance® End-to-End Solutions. Alteogen selected Merck to develop and produce recombinant biologics for the development and clinical...

UCB and Microsoft have announced a new multi-year, strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with UCB’s drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets...

The Egyptian Drug Authority has approved the Russian Direct Investment Fund’s (RDIF) Covid-19 vaccine, Sputnik V, under the emergency use authorisation (EUA) procedure. The Egyptian Drug Authority has approved the Russian Direct Investment Fund’s (RDIF) Covid-19 vaccine, Sputnik V, under...

C2 PHARMA, a pharmaceutical group established in 2014 focused on niche active pharmaceutical ingredient (APIs), has expanded its portfolio of APIs and botanical extracts throughout 2020 and will continue pursuing the expansion into 2021. Multiple regulatory filings have been...

The leading Australian CRO for biotechs, and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical continues to celebrate their strategic partnership with Medidata, and the accreditation of seven Medidata inhouse experts. The two organizations have been working...